alexa Epithelial To Mesenchymal Transition (EMT), As A Targeted Therapy For Multi Drug Resistance In Epithelial Ovarian Cancer
ISSN: 2157-7013

Journal of Cell Science & Therapy
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

4th World Congress on Cell Science & Stem Cell Research
June 24-26, 2014 Valencia Conference Centre, Valencia, Spain

Samir A Farghaly
ScientificTracks Abstracts: J Cell Sci Ther
DOI: 10.4172/2157-7013.S1.028
Abstract
W orldwide, over 230,000 women are diagnosed with ovarian cancer each year, and about 140,000 women die from the disease. In the USA, estimated new cases 22, 240 and 14, 030 deaths from ovarian cancer in 2013. Resistance to anticancer drugs is a major obstacle towards a successful treatment of ovarian cancer. Multidrug resistance (MDR) is cross-resistance of tumor cells to several structurally unrelated chemotherapeutic agents after exposure to a single cytotoxic drug. Drug resistance mechanisms in ovarian cancer cells have been explored, but they are still unclear. It has been shown that, Cisplatin-resistant COC1/DDP, which is derived from its parental ovarian cancer cell line COC1 by stepwise selection in vitro using cisplatin, and can also display cross-resistance to other anticancer drugs such as Adriamycin, mitomycin C, and 5-fluorouracil, is a useful cell model for investigating the mechanisms underlying MDR in ovarian cancer. It is not clear whether resistance is due to subpopulations of resistant cells, possibly with stem cell properties, already existing in the tumor before treatment, or is induced by mutations or epigenetic changes caused by chemotherapeutic drugs. Epithelial to mesenchymal transition (EMT) -related pathways provide targets for chemoresistant ovarian cancer therapy. Inhibition of integrin-linked kinase (ILK) increases the sensitivity of mesenchymal cells to EGFR-target therapy. In addition, Src kinase inhibitors effectively inhibit the growth of cells undergoing EMT. Furthermore, the inhibition of hedgehog signaling can prevent cancer cells from acquiring tumor-initiating property and undergoing EMT. RNA interference and microRNA are new technologies in drug development. Silencing of Snail by shRNA induces MET and reduces in vivo tumor growth. Specific silencers of endogenous miRNAs, antagomirs are shown to silence specific miRNAs in vivo . It follows that, microRNAs associated with EMT such as the miR-10b and miR-200 family could be a therapeutic target. In addition, the tumor microenvironment, which contributes to the maintenance of EMT, could be targeted. Furthermore, reducing EMT could also lessen the occurrence of anticancer drug resistance and effectively improve the efficacy of conventional cytotoxic therapy, to eradicate cancer cell, and cause minimal toxicity to normal cells. Further studies are needed to develop preclinical epithelial ovarian cancer models that mimic clinical cytotoxic drug resistance mechanisms related to epithelial to mesenchymal transition (EMT) in order to discover efficacious targeted therapy
Biography
Samir A Farghaly is a Physician/Scientist, and faculty member of the Medical College of Cornell University and The New York Presbyterian Hospital /Cornell University Medical Center, New York, NY, USA. He received his M.D Degree from University College London University (1985), and his PhD Degree in molecular biology from London university (1993). He received several clinical and research awards. He has been an invited speaker in several national and international conferences on cancer. He is a member of several national and international societies, organization and foundation of cancer and women health. He is an editor, member of editorial boards and reviewers of several medical journals of Oncology, Gynecology and Gynecological Cancers. He has published 74 articles. He is an editor of a book on ovarian cancer.
image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords